Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases.
Adjuvant chemotherapy
Breast cancer
Lymph node
Micrometastases
Survival
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
06
10
2020
accepted:
23
02
2021
pubmed:
16
3
2021
medline:
24
6
2021
entrez:
15
3
2021
Statut:
ppublish
Résumé
The axillary lymph node status is one of the most important prognostic factors in patients with early breast cancer. However, the impact of axillary lymph node micrometastases on survival remains unclear. There are no consistent recommendations for adjuvant chemotherapy (CHT). In this context, we aimed to investigate the impact of micrometastases on the clinical outcome of breast cancer patients according to the adjuvant CHT performed. We conducted a retrospective population-based registry study of 26,465 patients aged between 24 and 97 years with primary breast cancer diagnosed between 2003 and 2017. Of these patients, 8856 with early breast cancer were eligible for analysis: 8316 (93.9%) were node negative and 540 (6.1%) had lymph node micrometastases. The median follow-up was 7.2 years, with a confidence interval (CI) of 7.1-7.3 years. Patients with lymph node micrometastases (pN1mi) without adjuvant CHT have reduced 10-year overall survival (OS) and recurrence-free survival (RFS) compared to patients who had axillary lymph node micrometastases and received an adjuvant CHT. However, this effect disappeared after adjustment for age, tumor size and tumor grading. Furthermore, in the group of patients with lymph node micrometastases, the administration of adjuvant CHT did not improve OS or RFS, compared to patients with lymph node micrometastases without adjuvant CHT: hazard ratio for treated patients was 1.51 (95% CI 0.80-2.85, p = 0.208) for OS and 1.12 (95% CI 0.63-1.97, p = 0.705) for RFS. Patients with axillary lymph node micrometastases showed a comparable outcome to node negative patients and their outcome was not significantly improved with CHT. Thus, axillary lymph node micrometastases should not be considered in the treatment decision.
Sections du résumé
BACKGROUND
BACKGROUND
The axillary lymph node status is one of the most important prognostic factors in patients with early breast cancer. However, the impact of axillary lymph node micrometastases on survival remains unclear. There are no consistent recommendations for adjuvant chemotherapy (CHT). In this context, we aimed to investigate the impact of micrometastases on the clinical outcome of breast cancer patients according to the adjuvant CHT performed.
PATIENTS AND METHODS
METHODS
We conducted a retrospective population-based registry study of 26,465 patients aged between 24 and 97 years with primary breast cancer diagnosed between 2003 and 2017. Of these patients, 8856 with early breast cancer were eligible for analysis: 8316 (93.9%) were node negative and 540 (6.1%) had lymph node micrometastases.
RESULTS
RESULTS
The median follow-up was 7.2 years, with a confidence interval (CI) of 7.1-7.3 years. Patients with lymph node micrometastases (pN1mi) without adjuvant CHT have reduced 10-year overall survival (OS) and recurrence-free survival (RFS) compared to patients who had axillary lymph node micrometastases and received an adjuvant CHT. However, this effect disappeared after adjustment for age, tumor size and tumor grading. Furthermore, in the group of patients with lymph node micrometastases, the administration of adjuvant CHT did not improve OS or RFS, compared to patients with lymph node micrometastases without adjuvant CHT: hazard ratio for treated patients was 1.51 (95% CI 0.80-2.85, p = 0.208) for OS and 1.12 (95% CI 0.63-1.97, p = 0.705) for RFS.
CONCLUSION
CONCLUSIONS
Patients with axillary lymph node micrometastases showed a comparable outcome to node negative patients and their outcome was not significantly improved with CHT. Thus, axillary lymph node micrometastases should not be considered in the treatment decision.
Identifiants
pubmed: 33721148
doi: 10.1007/s10549-021-06162-2
pii: 10.1007/s10549-021-06162-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
715-727Références
Fisher B, Bauer M, Wickerham DL et al (1983) Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update Cancer 52:1551–1557. https://doi.org/10.1002/1097-0142(19831101)52:9%3c1551::AID-CNCR2820520902%3e3.0.CO;2-3
doi: 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3
pubmed: 6352003
Hatoum HA, Jamali FR, El-Saghir NS et al (2010) Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. Indian J Surg Oncol 1:68–75. https://doi.org/10.1007/s13193-010-0018-6
doi: 10.1007/s13193-010-0018-6
pubmed: 22930621
pmcid: 3420989
Viale G, Maiorano E, Mazzarol G et al (2001) Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 92:1378–1384. https://doi.org/10.1002/1097-0142(20010915)92:6%3c1378::AID-CNCR1460%3e3.0.CO;2-Y
doi: 10.1002/1097-0142(20010915)92:6<1378::AID-CNCR1460>3.0.CO;2-Y
pubmed: 11745213
van der Heiden-Loo M, Bezemer PD, Hennipman A et al (2006) Introduction of sentinel node biopsy and stage migration of breast cancer. Eur J Surg Oncol 32:710–714. https://doi.org/10.1016/j.ejso.2006.04.001
doi: 10.1016/j.ejso.2006.04.001
Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553. https://doi.org/10.1056/NEJMoa012782
doi: 10.1056/NEJMoa012782
pubmed: 12904519
Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927–933. https://doi.org/10.1016/S1470-2045(10)70207-2
doi: 10.1016/S1470-2045(10)70207-2
pubmed: 20863759
pmcid: 3041644
Maaskant AJG, Van De Poll-Franse LV, Voogd AC et al (2009) Stage migration due to introduction of the sentinel node procedure: a population-based study. Breast Cancer Res Treat 113:173–179. https://doi.org/10.1007/s10549-008-9913-8
doi: 10.1007/s10549-008-9913-8
pubmed: 18259855
Wittekind C (2016) TNM classification of malignant tumours, 8th edn. Wiley, New York, pp 151–158
Tjan-Heijnen VCG, Bult P, De Widt-Levert LM et al (2001) Micro-metastases in axillary lymph nodes: an increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure. Breast Cancer Res Treat 70:81–88. https://doi.org/10.1023/A:1012938825396
doi: 10.1023/A:1012938825396
pubmed: 11768607
Cserni G (1999) Metastases in axillary sentinel lymph nodes in breast cancer as detected by intensive histopathological work up. J Clin Pathol 52:922–924. https://doi.org/10.1136/jcp.52.12.922
doi: 10.1136/jcp.52.12.922
pubmed: 10711258
pmcid: 501663
Giuliano AE, Dale PS, Turner RR et al (1995) Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 222:394–401. https://doi.org/10.1097/00000658-199509000-00016
doi: 10.1097/00000658-199509000-00016
pubmed: 7677468
pmcid: 1234825
Weaver DL, Krag DN, Ashikaga T et al (2000) Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 88:1099–1107. https://doi.org/10.1002/(SICI)1097-0142(20000301)88:5%3c1099::AID-CNCR22%3e3.0.CO;2-7
doi: 10.1002/(SICI)1097-0142(20000301)88:5<1099::AID-CNCR22>3.0.CO;2-7
pubmed: 10699901
Patani N, Mokbel K (2009) The clinical significance of sentinel lymph node micrometastasis in breast cancer. Breast Cancer Res Treat 114:393–402. https://doi.org/10.1007/s10549-008-0021-6
doi: 10.1007/s10549-008-0021-6
pubmed: 18425678
de Boer M, van Deurzen CH, van Dijck JA et al (2009) Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J M 361:653–663. https://doi.org/10.1056/nejmoa0904832
doi: 10.1056/nejmoa0904832
Hansen NM, Grube B, Ye X et al (2009) Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol 27:4679–4684. https://doi.org/10.1200/JCO.2008.19.0686
doi: 10.1200/JCO.2008.19.0686
pubmed: 19720928
Grabau D, Jensen MB, Rank F, Blichert-Toft M (2007) Axillary lymph node micrometastases in invasive breast cancer: national figures on incidence and overall survival. APMIS 115:828–837. https://doi.org/10.1111/j.1600-0463.2007.apm_442.x
doi: 10.1111/j.1600-0463.2007.apm_442.x
pubmed: 17614850
Gobardhan PD, Elias SG, Madsen EVE et al (2009) Prognostic value of micrometastases in sentinel lymph nodes of patients with breast carcinoma: a cohort study. Ann Oncol 20:41–48. https://doi.org/10.1093/annonc/mdn535
doi: 10.1093/annonc/mdn535
pubmed: 18653702
Chen SL, Hoehne FM, Giuliano AE (2007) The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann Surg Oncol 14:3378–3384. https://doi.org/10.1245/s10434-007-9513-6
doi: 10.1245/s10434-007-9513-6
pubmed: 17899293
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2020) S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.3, AWMF, Registernummer: 032-045OL. pp 101, 143–168.
Langer I, Guller U, Viehl CT et al (2009) Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol 16:3366–3374. https://doi.org/10.1245/s10434-009-0660-9
doi: 10.1245/s10434-009-0660-9
pubmed: 19760047
Maaskant-Braat AJ, Voogd AC, van de Poll-Franse LV et al (2012) Axillary and systemic treatment of patients with breast cancer and micrometastatic disease or isolated tumor cells in the sentinel lymph node. Breast 21:524–528. https://doi.org/10.1016/j.breast.2012.03.008
doi: 10.1016/j.breast.2012.03.008
pubmed: 22516371
Taubenhansl C, Ortmann O, Gerken M et al (2019) Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients. Arch Gynecol Obstet. https://doi.org/10.1007/s00404-019-05387-3
doi: 10.1007/s00404-019-05387-3
pubmed: 31749031
pmcid: 7033056
Ignatov T, Eggemann H, Costa SD et al (2018) Endometrial cancer subtypes are associated with different patterns of recurrence. J Cancer Res Clin Oncol 144:2011–2017. https://doi.org/10.1007/s00432-018-2711-8
doi: 10.1007/s00432-018-2711-8
pubmed: 30027307
Ignatov A, Lebius C, Ignatov T et al (2019) Lymph node micrometastases and outcome of endometrial cancer. Gynecol Oncol 154:475–479. https://doi.org/10.1016/j.ygyno.2019.07.018
doi: 10.1016/j.ygyno.2019.07.018
pubmed: 31345606
von Elm E, Altman DG, Egger M et al (2008) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344–349. https://doi.org/10.1016/j.jclinepi.2007.11.008
doi: 10.1016/j.jclinepi.2007.11.008
Redig AJ, Mcallister SS (2013) Breast cancer as a systemic disease: a view of metastasis. J Intern Med 274:113–126. https://doi.org/10.1111/joim.12084
doi: 10.1111/joim.12084
pubmed: 23844915
pmcid: 3711134
Gill G (2009) Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 16:266–275. https://doi.org/10.1245/s10434-008-0229-z
doi: 10.1245/s10434-008-0229-z
pubmed: 19050973
Goyal A, Newcombe RG, Chhabra A, Mansel RE (2006) Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer: results of the ALMANAC validation phase. Breast Cancer Res Treat 99:203–208. https://doi.org/10.1007/s10549-006-9192-1
doi: 10.1007/s10549-006-9192-1
pubmed: 16541308
Krag DN, Anderson SJ, Julian TB et al (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8:881–888. https://doi.org/10.1016/S1470-2045(07)70278-4
doi: 10.1016/S1470-2045(07)70278-4
pubmed: 17851130
Veronesi U, Paganelli G, Viale G et al (2006) Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 7:983–990. https://doi.org/10.1016/S1470-2045(06)70947-0
doi: 10.1016/S1470-2045(06)70947-0
pubmed: 17138219
Rivera M, Merlin S, Hoda RS et al (2004) Minimal involvement of sentinel lymph node in breast carcinoma: prevailing concepts and challenging problems. Int J Surg Pathol 12:301–306. https://doi.org/10.1177/106689690401200402
doi: 10.1177/106689690401200402
pubmed: 15494855
Salhab M, Patani N, Mokbel K (2011) Sentinel lymph node micrometastasis in human breast cancer: an update. Surg Oncol 20:e195–e206. https://doi.org/10.1016/j.suronc.2011.06.006
doi: 10.1016/j.suronc.2011.06.006
pubmed: 21788132
Chagpar A, Middleton LP, Sahin AA et al (2005) Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer 103:1581–1586. https://doi.org/10.1002/cncr.20934
doi: 10.1002/cncr.20934
pubmed: 15747375
Kahn HJ, Hanna WM, Chapman JAW et al (2006) Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Breast J 12:294–301. https://doi.org/10.1111/j.1075-122X.2006.00267.x
doi: 10.1111/j.1075-122X.2006.00267.x
pubmed: 16848838
Wong SL, Chao C, Edwards MJ et al (2001) The use of cytokeratin staining in sentinel lymph node biopsy for breast cancer. Am J Surg 182:330–334. https://doi.org/10.1016/S0002-9610(01)00722-X
doi: 10.1016/S0002-9610(01)00722-X
pubmed: 11720665
Maaskant-Braat AJ, Van De Poll-Franse LV, Voogd AC et al (2011) Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study. Breast Cancer Res Treat 127:195–203. https://doi.org/10.1007/s10549-010-1086-6
doi: 10.1007/s10549-010-1086-6
pubmed: 20680679
Cote R, Giuliano AE, Hawes D et al (2010) ACOSOG Z0010: a multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. J Clin Oncol 28:CRA504. https://doi.org/10.1200/jco.2010.28.18_suppl.cra504
doi: 10.1200/jco.2010.28.18_suppl.cra504
Langer I, Marti WR, Guller U et al (2005) Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg 241:152–158. https://doi.org/10.1097/01.sla.0000149305.23322.3c
doi: 10.1097/01.sla.0000149305.23322.3c
pubmed: 15622003
pmcid: 1356858
Colpaert C, Vermeulen P, Jeuris W et al (2001) Early distant relapse in “node-negative” breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J Pathol 193:442–449. https://doi.org/10.1002/path.829
doi: 10.1002/path.829
pubmed: 11276002
Millis RR, Springall R, Lee AHS et al (2002) Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer 86:396–401. https://doi.org/10.1038/sj.bjc.6600070
doi: 10.1038/sj.bjc.6600070
pubmed: 11875706
pmcid: 2375207
De Mascarel I, Bonichon F, Coindre JM, Trojani M (1992) Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 66:523–527. https://doi.org/10.1038/bjc.1992.306
doi: 10.1038/bjc.1992.306
pubmed: 1520589
pmcid: 1977929
Cox CE, Kiluk JV, Riker AI et al (2008) Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg 206:261–268. https://doi.org/10.1016/j.jamcollsurg.2007.08.024
doi: 10.1016/j.jamcollsurg.2007.08.024
pubmed: 18222378
Reed J, Rosman M, Verbanac KM et al (2009) Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective east Carolina University/Anne Arundel Medical Center Sentinel Node Mult. J Am Coll Surg 208:333–340. https://doi.org/10.1016/j.jamcollsurg.2008.10.036
doi: 10.1016/j.jamcollsurg.2008.10.036
pubmed: 19317993
Montagna E, Viale G, Rotmensz N et al (2009) Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. Breast Cancer Res Treat 118:385–394. https://doi.org/10.1007/s10549-009-0446-6
doi: 10.1007/s10549-009-0446-6
pubmed: 19562480
Bae HW, Yoon KH, Kim JH et al (2018) Impact of micrometastatic axillary nodes on survival of breast cancer patients with tumors ≤2 cm. World J Surg 42:3969–3978. https://doi.org/10.1007/s00268-018-4725-4
doi: 10.1007/s00268-018-4725-4
pubmed: 29959491